Highlights Elite Pharmaceuticals, Inc.

Equities

ELTP

US28659T2006

Market Closed - OTC Markets Other stock markets 01:28:00 29/06/2024 am IST			5-day change	1st Jan Change
0.199 ^USD	-0.50%		+20.61%	+42.14%

20/05	Elite Pharmaceuticals Receives Fda Approval for Generic Methotrexate	CI
15/02	Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Elite Pharmaceuticals Receives Fda Approval for Generic Methotrexate	20/05	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	15/02	CI
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant	26/12	CI
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR to Marketing Partner Prasco, LLC	13/12	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	15/11	CI
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product	25/23/25	CI
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study	28/23/28	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	15/23/15	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product	20/23/20	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	15/23/15	CI
Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence Study	07/23/07	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	15/22/15	CI
Elite Pharmaceuticals Inc. and Lannett Company, Inc. Jointly Terminated the License, Supply and Distribution Agreement for Vigabatrin	11/22/11	CI
Elite Pharmaceuticals Inc. Receives Notification from Lannett Company, Inc. for Terminating the License, Supply and Distribution Agreement	27/22/27	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	16/22/16	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	30/22/30	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	15/22/15	CI
Elite Pharmaceuticals Inc. Signs License and Distribution Agreement with Dexcel Ltd	09/21/09	CI
Elite Pharmaceuticals, Inc. Renews Its License, Supply, and Distribution Agreement with Lannett Company, Inc	02/21/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Elite Pharmaceuticals, Inc.

Equities

ELTP

US28659T2006

Highlights

Filters